4results about How to "Help convert" patented technology

The application discloses a preparation method of a high-entropy MXene composite diaphragm coating, which comprises the following steps: in the first step, 2g of HE-MAX phase raw material powder is gradually added into a reaction container containing an HF solution to perform a chemical etching reaction, and meanwhile, the sample is magnetically stirred at 55 DEG C for 72 to 96h; in the second step, the obtained HE-MXene suspension is placed into a centrifugal tube, and the precipitate is collected by high-speed centrifugation, and the deionized water and anhydrous ethanol are repeatedly cleaned until the solution is close to neutral; in the third step, the obtained precipitate is vacuum dried at 60 DEG C for 12h to obtain HE-MXene nanosheet powder; in the fourth step, the HE-MXene and two-dimensional layered material powder are weighed according to a weight ratio of 7:3, and after grinding, they are dissolved into deionized water and stirred to prepare an HE-MXene suspension; in the fifth step, after magnetic stirring is used until the mixed state is reached, vacuum filtration is performed; in the sixth step, the obtained HE-MXene / two-dimensional layered material@PP is placed in a vacuum environment and dried at 40 DEG C for 6h, and finally, the modified diaphragm is cut into a disc with a diameter of 18mm.

This application relates to the field of NdFeB waste recycling, specifically to an environmentally friendly recycling method for NdFeB waste magnets. The method includes the following steps: crushing and separation, combined reaction, roasting, purification, and precipitation. The combined reaction involves adding sulfuric acid solution to the magnetic material for an initial reaction, followed by adding ammonium persulfate for a further reaction, resulting in a mixture. Purification involves adjusting the pH of the aqueous extract to 3-3.7, waiting for complete precipitation, and then filtering to obtain a filtrate. Precipitation involves adding the filtrate to a sodium carbonate solution for reaction and filtration to obtain rare earth precipitates. This application utilizes the combination of sulfuric acid and ammonium persulfate to convert rare earth elements and iron elements in the magnetic material into rare earth sulfate and iron sulfate as much as possible. Roasting further enhances the conversion effect, and then, under pH 3-3.7 conditions, the Fe in the aqueous extract... 3+ It is converted into ferric hydroxide precipitate as much as possible, and finally rare earth ions are precipitated using sodium carbonate solution for recovery.

The invention relates to a preparation method of an ionic liquid modified CuInS2 catalyst, which comprises the following steps: mixing soluble copper salt, soluble indium salt, thioacetamide and a solvent I to obtain a mixed solution, heating the mixed solution in a closed container to 140-180 DEG C, and washing and drying a solid product to obtain a CuInS2 material; and mixing the CuInS2 material, an ionic liquid and a solvent II, stirring, volatilizing the solvent, drying to obtain a pretreated catalyst, and roasting the pretreated catalyst in an inert gas or nitrogen atmosphere at 300-500 DEG C for 1-5 hours to obtain the ionic liquid modified CuInS2 catalyst. The method is simple and low in cost, and solves the problem of poor selectivity of reducing CO2 into ethylene through photo-thermal catalysis of an existing catalyst.

The invention discloses application of sitagliptin in preparation of a medicine for treating benign prostatic hyperplasia, and relates to the technical field of biological medicine. The invention discloses application of sitagliptin in preparation of a medicine for treating benign prostatic hyperplasia. The invention focuses on BPH, such as a core pathological target LAMA5 of collagen sedimentary BPH, screens an intervention drug with drug properties, and finds that the inhibition effect of a dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin on LAMA5 expression, collagen deposition and cell migration in a cell experiment is obviously superior to that of candidate drugs such as SB-525334 and olantinib. More importantly, sitagliptin is widely applied to treatment of type 2 diabetes in clinic as a classic hypoglycemic drug, is clear in safety and tolerance, is highly matched with clinical characteristics of high incidence of diabetes of patients with BPH, such as collagen sedimentary BPH, and has the unique advantage of taking both hypoglycemic and BPH treatment into consideration. And an ideal drug candidate is provided for solving the treatment dilemma of the subtype.